Luteal Phase Commencing of Growth Hormone

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00561769
Recruitment Status : Completed
First Posted : November 21, 2007
Last Update Posted : November 21, 2007
Ren-Tıp ART Center, Bursa, Turkey
Information provided by:
Gulhane School of Medicine

Brief Summary:
Commencing of growth hormone in luteal phase when follicular cohort for the next cycle is being gathered may increase mature oocytes in poor responder

Condition or disease Intervention/treatment
Infertility Drug: Norditropin pen

Study Type : Observational
Actual Enrollment : 61 participants
Observational Model: Case Control
Time Perspective: Prospective
Official Title: Growth Hormone co-Treatment Within a GnRH Agonist Long Protocol in Patients With Poor Ovarian Response
Study Start Date : January 2005
Actual Study Completion Date : November 2007

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Hormones

Group/Cohort Intervention/treatment
poor responder
Drug: Norditropin pen
12 IU per day

Primary Outcome Measures :
  1. mature oocyte number [ Time Frame: 2 years ]

Secondary Outcome Measures :
  1. pregnancy rate [ Time Frame: 2 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   20 Years to 40 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
poor response to previous COH in the same center

Inclusion Criteria:

  • Poor responder

Exclusion Criteria:

  • FSH >20 IU

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00561769

Ren Tıp ART Center
Bursa, Turkey, 16200
Sponsors and Collaborators
Gulhane School of Medicine
Ren-Tıp ART Center, Bursa, Turkey
Study Director: Tansu Kucuk, Assoc Prof GATA Ankara Identifier: NCT00561769     History of Changes
Other Study ID Numbers: GATA 2005-21
First Posted: November 21, 2007    Key Record Dates
Last Update Posted: November 21, 2007
Last Verified: November 2007

Keywords provided by Gulhane School of Medicine:
poor responder
growth hormone

Additional relevant MeSH terms:
Genital Diseases, Male
Genital Diseases, Female
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs